共找到13條詞條名為張發明的結果 展開
張發明
武漢大學藥學院教授
張發明，男，1964年生，博士，武漢大學藥學院教授、博士生導師，國家專家。
研究興趣與方向：降糖生物多肽的結構改造，多肽激動劑與受體的相互作用及信號傳導，多肽藥物的給葯途徑。高特異性抗VEGF單克隆抗體的人源化及藥理學研究。新型Check-Point 靶向抗癌及抗病毒藥物的生物化學及藥理學研究。
具有20多年生物醫藥教育及工作背景，專註於蛋白質多肽和基因工程藥物研發。迄今已在國際權威學術雜誌發表論文著作數20餘篇，其中以第一及通訊作者在《自然》雜誌上發表2篇論文，同時擁有9項蛋白質大分子藥物及設計的國際專利，在Eli Lilly 任職期間，3次獲最高總裁獎。近年來主持完成了幾個新葯的研製工作。其中，系列3.1類新葯已取得國家食品藥品監督管理局新葯臨床批件，兩個單克隆抗體創新葯在臨床申報階段。此外，他和他的團隊還憑藉在非天然氨基酸及其用於蛋白質生物葯修飾上的創新研究成果，開展了一系列長效、穩定生物多肽及大分子藥物的研發。
– 武漢大學，化學學士；
-武漢，化碩；
-科院研究，化博；
1990-1993美國德克薩斯大學西南醫學中心從事博士后研究工作；
1994-2005美國禮來製藥公司，高級科學家和藥物新葯開發部主管；
2005-2008美國印地安納大學化學和生物化學系任副教授；
2008-2010中美冠科生物醫藥有限公司總裁；
2012 - 至今 武漢大學藥學院教授。
具有20多年生物醫藥的研發經驗，特別是在蛋白質和基因工程藥物研發方面卓有成就
有2篇論文以第一作者在《NATURE》上發表，7項藥物設計及優化的美國專利。在Eli Lilly & Co.任職11年期間，主持或參與完成了多部葯政法規和藥品研髮指南性文件的編寫，為美國食品和藥品審評工作框架的制訂做出了重要貢獻。同時，張發明教授致力於企業管理和藥品的全球聯合研發、推動行業ISO標準、參與國際藥品標準的協調，嘗試多國晉級申報，領銜海外融資生產，發展三板塊市場合作等一系列中國醫藥研發能力提升和產品國際化的戰略實踐。2009年第一批武漢市“3551人才計劃”入選者及2010年 第五批入選者。
1. Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, Meng W, Ratnam M, Zhang F, Dann CE . Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15180-8.
2. Rogers T, Li P, Smiley D, DiMarchi RD, and Zhang F., (2007), Design, synthesize and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jul 1;63(Pt 7):599-601.
3. Singh J, Ling L, Sawyer JS, Lee W, Zhang F, Yingling JM., (2005), Successful discovery of TbRI (ALK5) kinase inhibitors using HTS, target-hopping and virtual screening, Chemistry Today, 23 (3): 35-38.
4. Hamdouchi C, Zhong B, Mendoza J, Zhang F et al. (2005), Structure-Based Design of a New Class of Highly Selective Aminoimidazo[1,2-á]pyridine-Based Inhibitors of Cyclin Dependent Kinases,bioorganic & Medicinal Chemistry Letters. 15 (7): 1943-1947.
5. Jaramillo C , Zhang F. et al (2004), Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation,bioorganic & Medicinal Chemistry Letters. 14(24): 6095-6099.
6. J. Singh, J. Yingling, Zhang F, et al (2004), Transforming the TGF-â pathway: Convergence of distinct lead generation strategies on a novel kinase pharmcophroe for TbRI, Current Opinion in Drug Discovery and Development 7(4): 10-20.
7. Al-Awar RS, Ray JE, Zhang F. etal (2004). Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors . Bioorg Med Chem Lett. 14(15): 3925-3928.
8. Sawyer JS, Beight DW, Zhang F, Yingling JM (2004). Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.Bioorg Med Chem Lett. 14(13): 3581-3584.
9. Hadouchi C, Keyser H, Zhang F, Brooks H, et al (2004). The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo(1,2-a]pyridines.Molecular Cancer Therapeutics. 3(1):1-9
10. Vincent J.-P, Johnson RB, Parsons S, Zhang F, Wang QM (2003). Identification of a C-terminal regulatory motif in hepatitis C virus RNA-dependent RNA polymerase: structural and biochemical analysis.J. Virology. 77: 9020-9028
11. Sanchez-Martinez C, Shih C, Zhu G, Dempsey JA, Zhang F(2003) . Studies on Cyclin Dependent Kinase Inhibitors:Indolo[2,3-a]pyrrolo[3,4-c]carbazoles versus Bis-indolylmaleimides,Bioorganic & Medicinal Chemistry Letters 13 :3841-3846.
12. Vieth M, Brooks H, Hamdouchi C, McMillen W, Sawyer JS, Yingling J, and ZhangF(2003). Combining Medicinal Chemistry with Chemogenomic and Computer-Aided Structure-Based Design in Development of Novel Kinase Inhibitors, Cell. Mol. Biol. Lett 8 (2A):566-567
13. Sawyer JS,Herron DK,Edward CR, Zhang F, and Yingling J (2003). Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-beta Type I Receptor Kinase Domain.Journal of Medicinal Chemistry 46 (19):3953-3956.
14. Wang QM, Hockman M, Staschke K, Zhang F, Parsons S (2002). Oligomerization and Cooperative RNA Synthesis Activity of HCV RNA-Dependent RNA Polymerase,J. Virology. 76 :3865-3872
15. Jin L, Briggs S, Clawson D, Schevitz R, Smiley D, Tashjian A, Zhang F (2000). “Crystal Structure of Human Parathyroid Hormone 1-34 at 0.9 Å Resolution”,J. Biol. Chem. 275:27238-27244.
16. Zhang F, Basinski M, DiMarchi RDet al. (1997) “Crystal Structure of theObese Protein Leptin-E100”, Nature387:206-209
17. Zhang J, Zhang F, Ebert D, Cobb MH, and Goldsmith EJ(1995) “Activity of the MAP Kinase ERK2 is Controlled by a Flexible Surface Loop”,Structure 3:299-307.
18. Zhang F, Strand A, Robbins D, Cobb MH, and Goldsmith EJ (1994) “Crystal Structure of MAP kinase ERK2 at 2.3Å Resolution”. Nature. 367: 704-711.
19. Zhang F, Robbins D, Cobb MH and Goldsmith EJ (1993) “ Crystallization and Preliminary X-ray Studies of Extracellular Signal-regulated Kinase-2/MAP kinase with an Incorporated His-tag”.J. Mol.Biol. 233: 550-552.
20. Lin Z, Li J , Zhang F and Tsou C-L (1993) “Structure of D-Glyceraldehyde-3-phosphate Dehydrogenase from Palinurus Versicolor Carrying the fluorescent NAD Derivatives at 2.7 Å Resolution”Arch. Biochem. Biophy. 302 :161-166.
21. Zhang F, Kobe B, Stewart CB, Rutter W and Goldsmith EJ (1991) “ Structural Evolution of an Enzyme Specificity: The Structure of Rat Carboxypeptidase A2 at 1.9 Å Resolution”.J. Biol. Chem. 266: 24606-24612.
1. Faming Zhang, John Beals, etal. (1997) “Obese Protein: Three-Dimensional Structure, Surface Properties, and Receptor-Binding Model”. In Leptin: The Voice of Adipose Tissue, W.F. Blum/W.Kiess/W.Rascher Eds. Edition J & J, 25-31.
2. Lei Jin, Armen Tashjian, and Faming Zhang (2003), “ Toward an Understanding of Human Parathyroid Hormone (PTH) Structure and Function”, in Parathyroid Hormone Molecular Biology, Tally Nareh/Justin Silver Eds. Landes Bioscience.
3. Faming Zhang, figure and text (21-23) contributions to college textbook “Fundamentals of Biochemistry”, 2/e by Voet and Pratt, John Wiley & Sons.
4. Faming Zhang, figure and text contributions to: Growth Hormone Replacement Therapy in Adults with Hypopituitary Disease. V1.1.
5. John Mayer, Faming Zhang, Richard DiMarchi (2007) “Insulin Structure and Function” , Biopolymers, April 4.
